302 related articles for article (PubMed ID: 26784941)
1. Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy.
Cashman TJ; Josowitz R; Johnson BV; Gelb BD; Costa KD
PLoS One; 2016; 11(1):e0146697. PubMed ID: 26784941
[TBL] [Abstract][Full Text] [Related]
2. Autonomous and Non-autonomous Defects Underlie Hypertrophic Cardiomyopathy in BRAF-Mutant hiPSC-Derived Cardiomyocytes.
Josowitz R; Mulero-Navarro S; Rodriguez NA; Falce C; Cohen N; Ullian EM; Weiss LA; Rauen KA; Sobie EA; Gelb BD
Stem Cell Reports; 2016 Sep; 7(3):355-369. PubMed ID: 27569062
[TBL] [Abstract][Full Text] [Related]
3. Adult human cardiac stem cell supplementation effectively increases contractile function and maturation in human engineered cardiac tissues.
Murphy JF; Mayourian J; Stillitano F; Munawar S; Broughton KM; Agullo-Pascual E; Sussman MA; Hajjar RJ; Costa KD; Turnbull IC
Stem Cell Res Ther; 2019 Dec; 10(1):373. PubMed ID: 31801634
[TBL] [Abstract][Full Text] [Related]
4. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
[TBL] [Abstract][Full Text] [Related]
5. Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes-a systematic review.
Eschenhagen T; Carrier L
Pflugers Arch; 2019 May; 471(5):755-768. PubMed ID: 30324321
[TBL] [Abstract][Full Text] [Related]
6. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
[TBL] [Abstract][Full Text] [Related]
7. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
[TBL] [Abstract][Full Text] [Related]
8. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
[TBL] [Abstract][Full Text] [Related]
9. Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with MYL2-R58Q-Mediated Apical Hypertrophic Cardiomyopathy Show Hypertrophy, Myofibrillar Disarray, and Calcium Perturbations.
Zhou W; Bos JM; Ye D; Tester DJ; Hrstka S; Maleszewski JJ; Ommen SR; Nishimura RA; Schaff HV; Kim CS; Ackerman MJ
J Cardiovasc Transl Res; 2019 Oct; 12(5):394-403. PubMed ID: 30796699
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Tissue Engineering Models of Inherited and Acquired Cardiomyopathies.
Turnbull IC; Mayourian J; Murphy JF; Stillitano F; Ceholski DK; Costa KD
Methods Mol Biol; 2018; 1816():145-159. PubMed ID: 29987817
[TBL] [Abstract][Full Text] [Related]
11. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.
Tanaka A; Yuasa S; Mearini G; Egashira T; Seki T; Kodaira M; Kusumoto D; Kuroda Y; Okata S; Suzuki T; Inohara T; Arimura T; Makino S; Kimura K; Kimura A; Furukawa T; Carrier L; Node K; Fukuda K
J Am Heart Assoc; 2014 Nov; 3(6):e001263. PubMed ID: 25389285
[TBL] [Abstract][Full Text] [Related]
12. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors.
Wijnker PJM; Dinani R; van der Laan NC; Algül S; Knollmann BC; Verkerk AO; Remme CA; Zuurbier CJ; Kuster DWD; van der Velden J
Cardiovasc Res; 2024 Mar; 120(3):301-317. PubMed ID: 38240646
[TBL] [Abstract][Full Text] [Related]
13. Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy.
Riaz M; Park J; Sewanan LR; Ren Y; Schwan J; Das SK; Pomianowski PT; Huang Y; Ellis MW; Luo J; Liu J; Song L; Chen IP; Qiu C; Yazawa M; Tellides G; Hwa J; Young LH; Yang L; Marboe CC; Jacoby DL; Campbell SG; Qyang Y
Circulation; 2022 Apr; 145(16):1238-1253. PubMed ID: 35384713
[TBL] [Abstract][Full Text] [Related]
14. Cardiomyocyte Apoptosis Is Associated with Contractile Dysfunction in Stem Cell Model of
Loiben AM; Chien WM; Friedman CE; Chao LS; Weber G; Goldstein A; Sniadecki NJ; Murry CE; Yang KC
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902340
[TBL] [Abstract][Full Text] [Related]
15. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.
Monteiro da Rocha A; Guerrero-Serna G; Helms A; Luzod C; Mironov S; Russell M; Jalife J; Day SM; Smith GD; Herron TJ
J Mol Cell Cardiol; 2016 Oct; 99():197-206. PubMed ID: 27620334
[TBL] [Abstract][Full Text] [Related]
16. Macrophages enhance contractile force in iPSC-derived human engineered cardiac tissue.
Lock RI; Graney PL; Tavakol DN; Nash TR; Kim Y; Sanchez E; Morsink M; Ning D; Chen C; Fleischer S; Baldassarri I; Vunjak-Novakovic G
Cell Rep; 2024 Jun; 43(6):114302. PubMed ID: 38824644
[TBL] [Abstract][Full Text] [Related]
17. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
[TBL] [Abstract][Full Text] [Related]
18. Modeling human protein aggregation cardiomyopathy using murine induced pluripotent stem cells.
Limphong P; Zhang H; Christians E; Liu Q; Riedel M; Ivey K; Cheng P; Mitzelfelt K; Taylor G; Winge D; Srivastava D; Benjamin I
Stem Cells Transl Med; 2013 Mar; 2(3):161-6. PubMed ID: 23430692
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy.
Mosqueira D; Mannhardt I; Bhagwan JR; Lis-Slimak K; Katili P; Scott E; Hassan M; Prondzynski M; Harmer SC; Tinker A; Smith JGW; Carrier L; Williams PM; Gaffney D; Eschenhagen T; Hansen A; Denning C
Eur Heart J; 2018 Nov; 39(43):3879-3892. PubMed ID: 29741611
[TBL] [Abstract][Full Text] [Related]
20. A Method for Contraction Force Measurement of hiPSC-Derived Engineered Cardiac Tissues.
Fujiwara Y; Deguchi K; Miki K; Nishimoto T; Yoshida Y
Methods Mol Biol; 2021; 2320():171-180. PubMed ID: 34302658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
